通过LegitScript认证,GLP-1电疗:2026年将获得全额认证

什么是LegitScript医疗保健商人认证?

LegitScript Healthcare Merchant Certification is the credential Meta and Google both require before a GLP-1 telehealth brand or online pharmacy can advertise prescription drugs to consumers. Meta's Advertising Standards state that online pharmacies and telehealth providers must hold active LegitScript certification before they even apply for drug-advertising authorization. Google's healthcare and medicines policy requires the same certification for telemedicine advertisers, and either LegitScript's certification or NABP accreditation for pharmacies targeting the US.

LegitScript itself is a private certification company, not a federal regulator. It audits your pharmacy licensing chain, prescribing workflow, physician credentials and marketing claims against a rulebook built from FDA, state medical board and DEA standards, then sells platforms a seal they can point to instead of reviewing every advertiser's compliance file themselves. Certification says nothing about whether the underlying drug is FDA-approved for the use being sold — it says the business selling it operates inside licensed, disclosed channels, and that distinction matters more than most applicants realize.

哪些GLP-1商业模式可以获得认证?

Telehealth operations dispensing FDA-approved branded GLP-1s through a licensed pharmacy pass certification at the highest rate, and narrow personalized-dosing compounding passes occasionally; almost everything else struggles. Branded fulfillment of semaglutide or tirzepatide through a state-licensed pharmacy gives an applicant a clean paper trail: an approved drug, a licensed dispenser, and no essentially-a-copy argument to defend. Compounding built on the pandemic-era drug shortage no longer has that shortage to point to.

FDA determined the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025; its enforcement-discretion wind-down for both drugs has since lapsed entirely. The surviving compounding pathway sits inside 21 U.S.C. 353a(b)(2) and 353b(d)(2)(B): a change made for an identified individual patient that produces a clinically significant difference, as determined and documented by the prescribing practitioner, not a program-wide dosing menu applied to every enrollee at intake. Read literally, the legal theory behind personalized-dosing GLP-1 programs was written for exceptional, documented cases, not a business model sold at scale, and that gap is exactly what state attorneys general and FDA warning letters keep finding.

• 通过许可药房实现品牌GLP-1:最高的认证通过率,因为FDA批准的药物和许可的发送器没有基本上一个副本的论据可以辩护.
• 个人化剂量组合与处方医生证实的患者特定剂量差异:狭窄,但它是21 U.S.C. 353a (b) ) (2) 和353b (d) ) (2) B (b) 规定的法律途径.
• 由于FDA对两种药物的执法处分期已过期,
• 食品和药物管理局表示,这些产品不能合法地合成,并直接警告远程卫生营销商.

申请需要什么,需要多长时间?

申请需要证明您的交付链中的每一个层都获得许可和披露,而不仅仅是填写表格.LegitScript希望您在每个州的药店获得国有许可证,医生和处方人员凭证,您的远程健康同意和处方协议,以及您的直播营销 广告创意,登陆页面和索赔 审查,而不是作为一个被清洁的版本提交批准.

LegitScript does not publish a fixed review timeline, so any specific day count circulating among consultants should be treated as unverified until you confirm it directly with LegitScript. Applicants describe review stretching from several weeks to multiple months depending on how complete the documentation is on first submission and how many follow-up requests the compliance claims trigger. Programs recruiting through affiliate networks tend to draw more scrutiny here, since affiliate-driven GLP-1 telehealth funnels often run creative the core brand never directly reviewed before it went live.

利格斯克里普特认证每年需要多少钱?

根据LegitScript的公开费用表,目前无法对首要来源进行核实.至少期望两条成本线:与审查您的文档相关的初始申请费,以及一次性年度监控费,用于资助LegitScript对您的营销和许可状态的持续监控.

根据法律规定,如果您的营销要求或许可证不符合规定,LegitScript会定期重新认证,并且可以撤销停留周期中期的资金.因此,作为一次性合规操作项目,以及法律审查广告副本,预算认证与实际持有认证的运营商如何运行账本相匹配.

为什么GLP-1的营销商失败了认证?

Most compounded-GLP-1 marketers fail because their own marketing supplies the evidence against them. FDA's March 2026 warning letter to Gram Peptides shows the pattern: retatrutide and tirzepatide pages labeled "Research Use Only, not intended for human consumption" were still classified as unlawful new drugs, because FDA held that mechanism-of-action and weight-loss language on the website, not the disclaimer, established human-use intent under 21 CFR 201.128. The same letter treated bundling bacteriostatic water alongside peptides that require reconstitution as independent evidence the water was intended for injection.

美国食品和药物管理局 (FDA) 宣布,在2026年3月3日,FDA向远程卫生公司发布了30封警告信,警告称,这些广告与FDA批准的产品或在远程卫生公司的商标下标签复合药品具有相同性,而没有资格采购,FDA表示,在前六个月中发出了更多误导性广告信件,而不是在整个上十年中发出.

State regulators are not waiting on FDA either. Alabama's attorney general sued Aurora IV and Wellness in November 2025 for injecting patients with material labeled for laboratory research only while marketing it as pharmaceutical-grade tirzepatide and semaglutide, a case that ended in permanent closure and roughly $24,000 in damages and penalties. Connecticut's attorney general separately sued a raw-peptide distributor and later issued cease-and-desist letters over corporate-practice-of-medicine violations at weight-loss clinics. An applicant carrying any of this history walks into LegitScript review with an enforcement record already working against it, the kind of exposure mapped in the 2026 GLP-1 telehealth risk map.

证书对Meta和Google的实现了什么?

认证是两种平台上药品广告的入口门票,不是保证一旦你持有它.Meta限制了处方药的推广到在线药店,远程医疗提供商和制药制造商,并要求前两类在申请自己的内部授权之前携带活跃的LegitScript认证;然后针对性在美国,加拿大和新西兰上限.Google运行一个平行门口:药店需要LegitScript医疗保健商人认证或NABP认证,远程医疗广告商需要LegitScript认证,在两种情况下,广告商也必须完成Google的自己的认证过程.

Certification does not retire claims risk once ads start running. Google's Unreliable claims and Unacceptable business practices policies still catch efficacy language a certified advertiser publishes, and Meta's Health and Wellness rules separately ban clickbait weight-loss framing and "statements of inferiority about physical appearance" regardless of certification status. The mechanics of which restricted terms you can bid on, and which trigger an outright ban, sit in Daily Intel's walkthrough of Google Ads certification and restricted terms.

批准后,会进行什么持续监测?

认证不是一次性的标志.LegitScript在批准后会继续监测您的营销和许可,并且两家广告平台都在不断地将自己的审查叠加在上面.Meta表示其广告评审"主要依赖于自动工具"检查每一个广告和其登陆页面,而不仅仅是最初提交,并且广告可以在开启后再次进行审查,无论帐户运行时间多久.Google通过其广告商验证程序进行了类似的持续检查,该程序可以将先前验证的帐户重新检查.

Losing certification or drifting out of compliance carries consequences beyond the ad account. Meta's Account Integrity policy allows restricting not just one ad but the whole Business Account and its associated assets when a pattern of violations is found, and Google's Abusing the ad network policy suspends accounts outright for circumvention with no prior warning and no path back onto the platform. Operators running these funnels who also process high-ticket chargebacks should treat this as one connected risk surface, a pattern covered in Daily Intel's look at peptide and GLP-1 telehealth chargeback disputes.

快速决策检查列表

实际问题是,读者是否需要更快的证据来了解已经在VSL驱动的直接反应中发挥作用,特别是在营养品,补充剂,GLP-1,减肥,血糖以及相邻的高意向健康市场上.

对于下一个决定,最重要的是根据市场活动的例子:哪个子要测试,哪个索赔风格是风险的,哪个道结构是常见的,哪个语言市场正在移动,以及竞争对手的创意是否可能是早期,扩展或已经和.

• 如果您需要直接答案,请从TL;DR开始.
• 快速比较交易.
• 使用常见问题,以提供答案机准备的总结.
• 根据该决定,使用CTA,而不是理论,需要实时VSL和广告示例.

报道报道报道报道报道报道报道报道报道报道报道报道

广告客户在视觉创意之外所做的事情理解的环境,包括广告客户在黑帽,灰帽和白帽广告模式中,具有足够的背景.实际的区别是,用户不仅看到屏幕截图;他们正在看到VSL,广告,道,转录,UTM文本和将资产转化为决定的研究笔记.

这很重要,因为直接响应的附属公司并不属于一个清洁类别.减肥活动可能使用白帽合规广告,灰帽预登陆器,更具侵略性的VSL和围绕上和恢复设计的收购路径.有用的智能平台需要捕获这种频谱,而不是假装每一次获胜的活动都像公共品牌广告.

黑帽,白帽和多语言信号覆盖

每日英特尔在黑帽和白帽式运动中追踪模式,以便运营商能够理解市场而不盲目复制风险.白帽的例子有助于耐用性和合规性审查;黑帽和灰帽的例子揭示了压力点,子,机制和道结构,这些机制可能会推动支出,但需要在使用前仔细适应.

该目录也为全球运营商构建,VSL和广告引用涵盖14多种语言和不同的当地语法.这对于巴西,拉塔姆,欧洲,MENA,印度和非原生英语附属公司来说是一个关键优势,他们需要看到市场的相同愿望如何跨文化转化,而不是仅仅研究美国英语广告.

如何负责任地使用情报

目标是建模,而不是复制. 使用每日英特尔来了解结构:,机制,证明,要求强度,深度,提供经济学和和阶段.然后构建原创创意,审查要求,并适应角度流量来源,国家,语言和合规要求的竞选.

强大的工作流程在行动之前比较多个例子.如果同一机制在多种语言,多种广告商和多种道变体中出现,它可能是持久的市场信号.如果这个例子只出现一次或依赖于攻击性索赔,请把它视为研究线索而不是竞选模板.

• 模型结构,而不是保护的创意资产.
• 单独的白帽耐用性与黑帽说服压力.
• 比较美国英语的例子与拉塔姆,欧洲和其他语言变体.
• 通过转录和接笔来构建原始简单.
• 保持合规性审查与市场研究分开.

方法论与来源背景

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Nutra niche intelligence directory, Is Selling Research Peptides Legal?, Best Peptides Supplier: The Practical Version, How to Sell Nutraceutical Products, Nutraceutical Company Manufactured Whey Protein, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.